Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. Monocyte chemoattractant protein-1 (MCP-1) is highly expressed in various malignancies and promotes carcinogenesis. The aim of the study was to investigate the association between MCP-1 genetic polymorphisms and the susceptibility to ovarian cancer. MCP-1 rs1024611A/G and rs3760396C/G polymorphisms were examined in 257 ovarian cancer patients and 273 healthy controls. We found that distributions of rs1024611GG genotype and rs3760396GG genotype were clearly increased in ovarian cancer cases compared to healthy donors (odds ratio [OR]=1.93, 95% confidence interval [CI]: 1.13–3.29, p=0.015; OR=3.89, 95% CI: 1.63–9.33, p=0.001). Stratification analyses revealed that patients with serous papillary type had further increased percentage of rs3760396GG genotype than those with other types (OR=3.89, 95% CI: 1.11–13.66, p=0.024). In addition, we evaluated the possible effect of MCP-1 polymorphisms on gene expression by examining the serum level of MCP-1 in patients and controls. Data revealed that subjects carrying rs1024611AG and GG genotypes had a significantly higher serum level of MCP-1 than those with AA genotype. These data suggest that MCP-1 rs1024611A/G and rs3760396C/G polymorphisms are associated with increased susceptibility to ovarian cancer, in which rs1024611A/G may increase serum level of MCP-1 in the Chinese population.
Get full access to this article
View all access options for this article.
References
1.
ArakelyanA., ZakharyanR., HambardzumyanM., PetrkovaJ., OlssonM.C., PetrekM., and BoyajyanA. (2014). Functional genetic polymorphisms of monocyte chemoattractant protein 1 and C-C chemokine receptor type 2 in ischemic stroke. J Interferon Cytokine Res, 34, 100–105.
2.
ArnoldJ.M., HuggardP.R., CummingsM., RammG.A., and Chenevix-TrenchG. (2005). Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinoma. Br J Cancer, 92, 2024–2031.
3.
BaiJ., LiX., TongD., ShiW., SongH., and LiQ. (2013). T-cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and prognosis of non-small-cell lung cancer. Tumour Biol, 34, 805–809.
4.
BaiJ., SongH., CaiC., ZhangM., XuS., and TanJ. (2012). The association of monocyte chemotactic protein-1 and CC chemokine receptor 2 gene variants with chronic obstructive pulmonary disease. DNA Cell Biol, 31, 1058–1063.
5.
FurukawaS., SoedaS., KikoY., SuzukiO., HashimotoY., WatanabeT., NishiyamaH., TasakiK., HojoH., AbeM., and FujimoriK. (2013). MCP-1 promotes invasion and adhesion of human ovarian cancer cells. Anticancer Res, 33, 4785–4790.
6.
GrzegorzewskaA.E., PajzderskiD., SowinskaA., and JagodzinskiP.P. (2014). Monocyte chemoattractant protein-1 gene (MCP-1-2518 A/G) polymorphism and serological markers of hepatitis B virus infection in hemodialysis patients. Med Sci Monit, 20, 1101–1116.
7.
HanS., FengS., YuanG., DongT., GaoD., LiangG., and WeiX. (2014). Lysyl oxidase genetic variants and the prognosis of glioma. APMIS, 122, 200–205.
8.
HasegawaM., and SatoS. (2008). The roles of chemokines in leukocyte recruitment and fibrosis in systemic sclerosis. Front Biosci, 13, 3637–3647.
9.
KalinowskaA., and LosyJ. (2008). Investigational C-C chemokine receptor 2 antagonists for the treatment of autoimmune diseases. Expert Opin Invest Drugs, 17, 1267–1279.
10.
KligermanS., and WhiteC. (2011). Epidemiology of lung cancer in women: risk factors, survival, and screening. AJR Am J Roentgenol, 196, 287–295.
11.
Kudo-SaitoC., ShirakoH., OhikeM., TsukamotoN., and KawakamiY. (2013). CCL2 is critical for immunosuppression to promote cancer metastasis. Clin Exp Metastasis, 30, 393–405.
12.
LeonardE.J., SkeelA., and YoshimuraT. (1991). Biological aspects of monocyte chemoattractant protein-1 (MCP-1). Adv Exp Med Biol, 305, 57–64.
13.
LiX., ShiW., YuG., LinL., YangB., LiJ., GuoW., TangC., WangH., GaoH., QinH., LiuY., and LiuX. (2012). Interleukin-4-590T/C polymorphism influences the susceptibility to nonsmall cell lung cancer. DNA Cell Biol, 31, 797–800.
14.
LiuG.X., ZhangX., LiS., KoiicheR.D., SindsceiiJ.H., and SongH. (2013). Monocyte chemotactic protein-1 and CC chemokine receptor 2 polymorphisms and prognosis of renal cell carcinoma. Tumour Biol, 34, 2741–2746.
15.
LuY., CaiZ., XiaoG., KellerE.T., MizokamiA., YaoZ., RoodmanG.D., and ZhangJ. (2007). Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res, 67, 3646–3653.
16.
MaH., ShuY., PanS., ChenJ., DaiJ., JinG., HuZ., and ShenH. (2011). Polymorphisms of key chemokine genes and survival of non-small cell lung cancer in Chinese. Lung Cancer, 74, 164–169.
17.
MoriyaR., TakahashiK., KitaharaA., OnumaH., HandaK., SumitaniY., TanakaT., KatsutaH., NishidaS., ItagakiE., InukaiK., and IshidaH. (2014). Possible involvement of PI3K-dependent pathways in the increased VEGF120 release from osteoblastic cells preloaded with palmitate in vitro. Biochem Biophys Res Commun, 445, 275–281.
18.
PalmieriO., LatianoA., SalvatoriE., ValvanoM.R., BossaF., LatianoT., CorritoreG., di MauroL., AndriulliA., and AnnesecV. (2010). The -A2518G polymorphism of monocyte chemoattractant protein-1 is associated with Crohn's disease. Am J Gastroenterol, 105, 1586–1594.
19.
PhamM.H., BonelloG.B., CastiblancoJ., LeT., SigalaJ., HeW., and MummidiS. (2012). The rs1024611 regulatory region polymorphism is associated with CCL2 allelic expression imbalance. PLoS One, 7, e49498.
20.
ProudfootA.E., de SouzaA.L., and MuzioV. (2008). The use of chemokine antagonists in EAE models. J Neuroimmunol, 198, 27–30.
21.
RongY., SongH., YouS., ZhuB., ZangH., ZhaoY., LiY., WanZ., LiuH., ZhangA., XiaoL., and XinS. (2013). Association of Toll-like receptor 3 polymorphisms with chronic hepatitis B and hepatitis B-related acute-on-chronic liver failure. Inflammation, 36, 413–418.
22.
SanfordD.E., BeltB.A., PanniR.Z., MayerA., DeshpandeA.D., CarpenterD., MitchemJ.B., Plambeck-SuessS.M., WorleyL.A., GoetzB.D., Wang-GillamA., EberleinT.J., DenardoD.G., GoedegebuureS.P., and LinehanD.C. (2013). Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res, 19, 3404–3415.
23.
ShiW., YangB., LiX., SunS., WangL., and JiaoS. (2012). The effect of lysyl oxidase polymorphism on susceptibility and prognosis of nonsmall cell lung cancer. Tumour Biol, 33, 2379–2383.
24.
SuX., YeJ., HsuehE.C., ZhangY., HoftD.F., and PengG. (2010). Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol, 184, 1630–1641.
25.
TanakaT., TeradaM., AriyoshiK., and MorimotoK. (2010). Monocyte chemoattractant protein-1/CC chemokine ligand 2 enhances apoptotic cell removal by macrophages through Rac1 activation. Biochem Biophys Res Commun, 399, 677–682.
26.
TseK.P., TsangN.M., ChenK.D., LiH.P., LiangY., HsuehC., ChangK.P., YuJ.S., HaoS.P., HsiehL.L., and ChangY.S. (2007). MCP-1 promoter polymorphism at 2518 is associated with metastasis of nasopharyngeal carcinoma after treatment. Clin Cancer Res, 13, 6320–6326.
27.
WintgesK., BeilF.T., AlbersJ., JeschkeA., SchweizerM., ClaassB., TiegsG., AmlingM., and SchinkeT. (2013). Impaired bone formation and increased osteoclastogenesis in mice lacking chemokine (C-C motif) ligand 5 (Ccl5). J Bone Miner Res, 28, 2070–2080.
28.
WojnarowiczP., GambaroK., de LadurantayeM., QuinnM.C., ProvencherD., Mes-MassonA.M., and ToninP.N. (2012). Overexpressing the CCL2 chemokine in an epithelial ovarian cancer cell line results in latency of in vivo tumourigenicity. Oncogenesis, 1, e27.
29.
YoshimuraT., and LeonardE.J. (1991). Human monocyte chemoattractant protein-1 (MCP-1). Adv Exp Med Biol, 305, 47–56.
